Sex: M
Vaccine: COVID19
Symptoms: Physical examination, Pustule, Rash erythematous, White blood cell count, White blood cell count increased
Clinical narrative: GENERALIZED DISTRIBUTION (50% BODY SURFACE AREA) OF ERYTHEMATOUS PLAQUES, RASH SPARED THE FACE, GENITALS, MUCOSA; NON-FOLICULAR PUSTULES; ACRAL SWELLING; ELEVATED WHITE BLOOD CELL  COUNT; ABSOLUTE NEUTROPHILIA; ELEVATED EOSINOPHIL COUNT; CREATININE ELEVATED; IPSILATERAL ARM DISCOMFORT INCLUDING AXILLA; This spontaneous report was received from literature. This report concerned a 74 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included vision loss of left eye, neurogenic bladder, obstructive sleep apnea, sulfa drug allergy, adrenal insufficiency, panhypopituitarism, and past history included craniopharyngioma resection, and other pre-existing medical conditions included no recent illness, no prior vaccination-related reaction. The patient experienced drug allergy when treated with amoxicillin, and clavulanic acid.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN expiry :unknnown) dose, start therapy date were not reported total 1 dose is administered for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. Concomitant medications included prednisone for adrenal insufficiency.  On an unspecified date, the subject experienced generalized distribution (50% body surface area) of erythematous plaques, rash spared the face, genitals, mucosa, non-folicular pustules, ipsilateral arm discomfort including axilla, acral swelling, elevated white blood cell count, absolute neutrophilia, elevated eosinophil count, and creatinine elevated, and was hospitalized (date unspecified).  Laboratory data (dates unspecified) included: Biopsy (NR: not provided) Epidermal spongiosis with focal, Direct immunofluorescence (NR: not provided) negative, Eosinophil count (NR: not provided) 1.6 10*9/L, Neutrophil count (NR: not provided) 92.10 %, Physical examination (NR: not provided) 50% body surface area of erythematous plaques, and White blood cells (NR: 3.7 - 9.7) 19.7 10*9/L, Creatinine (NR: not provided) 1.06 mg/dL. Treatment medications (dates unspecified) included: prednisone. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from generalized distribution (50% body surface area) of erythematous plaques, rash spared the face, genitals, mucosa, and non-folicular pustules, ipsilateral arm discomfort including axilla, acral swelling, elevated white blood cell count, absolute neutrophilia, elevated eosinophil count, and creatinine elevated. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210556006- covid-19 vaccine ad26.cov2.s- generalized distribution (50% body surface area) of erythematous plaques, rash spared the face, genitals, and mucosa, non-follicular pustules, Acral swelling, elevated white blood cell count, absolute neutrophilia, elevated eosinophil count, creatinine elevated, ipsilateral arm discomfort, including the axilla. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).